Lai Haiyang, Wu Ketong, Liu Yang, Li Dan, Peng Tao, Wan Yuan, Zhang Bo
Department of Interventional Center, Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Front Oncol. 2025 Jun 18;15:1599582. doi: 10.3389/fonc.2025.1599582. eCollection 2025.
The purpose of this study was to assess the efficacy and safety of self-expandable metal stents (SEMS) in treating anastomotic obstruction associated with recurrent gastric cancer.
Ten patients with anastomotic obstruction in recurrent gastric cancer were treated by SEMS implantation under fluoroscopic guidance. All patients presented with refractory nausea, vomiting and complete inability to tolerate oral intake before stent placement, requiring total parenteral nutrition (TPN). Clinical data were retrospectively analyzed the technical and clinical success rates, stent patency and complication rates.
SEMS was successfully implanted in all patients, and clinical success rate was 100%. The operations were subtotal gastrectomy with Billroth-II reconstruction (n = 3), radical distal gastrectomy (n = 3), total gastrectomy with esophagojejunostomy (n = 3), and palliative gastrojejunostomy (n = 1). Three patients developed stent occlusion due to intrastent tumor ingrowth secondary to disease progression after initial anastomotic stent placement, and underwent secondary stent implantation with successful maintenance of patency postoperatively. One patient developed stent obstruction due to food impaction on postoperative day 10, which was managed endoscopically with successful restoration and maintenance of luminal patency. The mean stent patency was 78 d (range, 8-225 d). No serious complications, such as anastomotic leakage, stent migration and bleeding were observed in these patients.
Fluoroscopically-guided SEMS placement represents a technically safe and clinically effective intervention for managing anastomotic obstructions in recurrent gastric cancer. SEMS placement offers rapid symptom relief, shorter hospital stays, and improved quality of life compared to surgical alternatives in this patient population. Thus, based on its technical feasibility and clinical outcomes, this method warrants primary consideration in palliative treatment algorithms.
本研究旨在评估自膨式金属支架(SEMS)治疗复发性胃癌相关吻合口梗阻的疗效和安全性。
10例复发性胃癌吻合口梗阻患者在透视引导下接受SEMS植入治疗。所有患者在支架置入前均出现难治性恶心、呕吐,完全无法耐受经口进食,需要全胃肠外营养(TPN)。回顾性分析临床资料,包括技术成功率、临床成功率、支架通畅率和并发症发生率。
所有患者均成功植入SEMS,临床成功率为100%。手术方式为毕Ⅱ式胃大部切除术(n = 3)、根治性远端胃切除术(n = 3)、食管空肠吻合全胃切除术(n = 3)和姑息性胃空肠吻合术(n = 1)。3例患者在初次吻合口支架置入后,由于疾病进展导致支架内肿瘤长入而发生支架闭塞,并接受了二次支架植入,术后成功维持了通畅。1例患者在术后第10天因食物嵌塞导致支架阻塞,经内镜处理后成功恢复并维持了管腔通畅。支架平均通畅时间为78天(范围8 - 225天)。这些患者未观察到严重并发症,如吻合口漏、支架移位和出血。
透视引导下SEMS置入是治疗复发性胃癌吻合口梗阻的一种技术安全、临床有效的干预措施。与该患者群体的手术替代方案相比,SEMS置入可快速缓解症状,缩短住院时间,并改善生活质量。因此,基于其技术可行性和临床结果,该方法在姑息治疗方案中值得优先考虑。